Why This Genomics ETF Is a Long-Term Winner

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) turns six years old next month and over that time, it’s developed a reputation as one of the best-performing healthcare ETFs, biotechnology or otherwise. That success is attributable to the ability of ARK Invest’s managers to...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.